137 related articles for article (PubMed ID: 37683819)
1. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission?
Mathian A; Arnaud L; Ruiz-Irastorza G
Autoimmun Rev; 2024 Jan; 23(1):103446. PubMed ID: 37683819
[TBL] [Abstract][Full Text] [Related]
2. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
[TBL] [Abstract][Full Text] [Related]
3. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
Fasano S; Coscia MA; Pierro L; Ciccia F
Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836
[TBL] [Abstract][Full Text] [Related]
4. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual.
Ji L; Xie W; Zhang Z
Rheumatology (Oxford); 2021 Dec; 60(12):5517-5526. PubMed ID: 33576768
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
[TBL] [Abstract][Full Text] [Related]
6. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.
Ji L; Gao D; Hao Y; Huang H; Wang Y; Deng X; Geng Y; Zhang Z
Rheumatology (Oxford); 2022 Dec; 62(1):181-189. PubMed ID: 35412598
[TBL] [Abstract][Full Text] [Related]
7. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.
Ji L; Xie W; Fasano S; Zhang Z
Lupus Sci Med; 2022 Jan; 9(1):. PubMed ID: 34996857
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus and glucocorticoids: A never-ending story?
Paredes-Ruiz D; Ruiz-Irastorza G; Amoura Z
Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101873. PubMed ID: 37957076
[TBL] [Abstract][Full Text] [Related]
10. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
[TBL] [Abstract][Full Text] [Related]
11. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
12. Predicting lupus low disease activity state and remission in SLE: novel insights.
Gao D; Hao Y; Fan Y; Ji L; Zhang Z
Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
[No Abstract] [Full Text] [Related]
13. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.
Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F
Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900
[TBL] [Abstract][Full Text] [Related]
14. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
15. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
16. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
17. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
[TBL] [Abstract][Full Text] [Related]
18. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
Ruiz-Arruza I; Ugarte A; Cabezas-Rodriguez I; Medina JA; Moran MA; Ruiz-Irastorza G
Rheumatology (Oxford); 2014 Aug; 53(8):1470-6. PubMed ID: 24681836
[TBL] [Abstract][Full Text] [Related]
20. Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study.
Sada KE; Katayama Y; Asano Y; Hayashi K; Miyawaki Y; Ohashi K; Katsuyama E; Katsuyama T; Takano-Narazaki M; Matsumoto Y; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M; Yajima N
Lupus Sci Med; 2022 Sep; 9(1):. PubMed ID: 36167483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
